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Fluoroquinolone resistance in Streptococcus pneumo-
niae is primarily mediated by point mutations in the
quinolone resistance–determining regions of gyrA and
parC. Antimicrobial resistance mutations in housekeeping
genes often decrease fitness of microorganisms. To inves-
tigate the fitness of quinolone-resistant S. pneumoniae
(QRSP), the relative growth efficiencies of 2 isogenic
QRSP double mutants were compared with that of their
fluoroquinolone-susceptible parent, EF3030, by using
murine nasopharyngeal colonization and pneumonia mod-
els. Strains containing the GyrA: Ser81Phe, ParC:
Ser79Phe double mutations, which are frequently seen in
clinical QRSP, competed poorly with EF3030 in competitive
colonization or competitive lung infections. However, they
efficiently produced lung infection even in the absence of
EF3030. The strain containing the GyrA: Ser81Phe, ParC:
Ser79Tyr double mutations, which is seen more frequently
in laboratory-derived QRSP than in clinical QRSP, demon-
strated reduced nasal colonization in competitive or non-
competitive lung infections. However, the strain was
equally able to cause competitive or noncompetitive lung
infections as well as EF3030. 
S
treptococcus pneumoniae causes otitis media, bac-
teremia, and meningitis and is a leading cause of com-
munity-acquired bacterial pneumonia worldwide.
Pneumococcal infections are commonly treated with β-
lactams, macrolides, and, increasingly, fluoroquinolones.
Pneumococcal resistance to each of these drug classes has
increased in recent years (1,2). Initially, antimicrobial
resistance in a pathogen may come at a cost: modifications
that allow survival in the presence of antimicrobial drugs
may render the pathogen less efficient at host infection,
even in the absence of the antimicrobial agent (3). Little is
known about the fitness of antimicrobial-resistant S. pneu-
moniae (4–8). The emergence of quinolone-resistant S.
pneumoniae (QRSP) appears to be more dependent on flu-
oroquinolone selection of de novo spontaneous point
mutations in the quinolone resistance–determining regions
(QRDRs) of the topoisomerase genes gyrA and parC than
on clonal dissemination (9–13). However, some studies
reported occurrences of clonal relatedness among QRSP
(11,14–16). 
To investigate the relative fitness of QRSP, we conduct-
ed a competition study of a fluoroquinolone-susceptible
clinical strain of S. pneumoniae (EF3030) with 2 of its flu-
oroquinolone-resistant isogenic mutants that had 2 com-
mon QRDR point mutation combinations. These 3 strains
were analyzed by using an in vitro growth model, an in
vivo nasopharyngeal colonization model, and an in vivo
pneumonia model. We also carried out the nasopharyngeal
colonization and pneumonia infections in the absence of
competition to assess the ability of the mutants to colonize
and to produce pneumonia in the absence of competition
from the susceptible parent. To our knowledge, this is the
first extensive investigation into the relative fitness of
QRSP using in vitro models in combination with nasopha-
ryngeal colonization and lung infection models.
Materials and Methods
Generation of Fluoroquinolone-resistant Mutants
For this study, naturally occurring fluoroquinolone
resistance mutations were placed in the serotype 19F
strain EF3030 by using established techniques (17).
Briefly, 1,325-bp fragments of gyrA and 778 bp of parC
were amplified by polymerase chain reaction from 2 pre-
viously characterized (18) clinical isolates of QRSP
(CT01147 and UAB169; gemifloxacin MIC = 1 µg/mL)
by using the primers shown in the Table. Phenotypic
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gyrA fragment, and these were selected on 0.06 µg/mL
gemifloxacin (SmithKline Beecham Pharmaceuticals,
Collegeville, PA, USA). Second-step transformants were
generated by the introduction of the second fragment
(gyrA or  parC) into first-step transformants, and these
were selected on 0.5 µg/mLgemifloxacin, a concentration
that effectively inhibited the growth of first-step mutants
and permitted the growth of second-step mutants. Two of
the isogenic gyrA,  parC double mutants, Phe/Phe and
Phe/Tyr, were chosen for fitness studies. In addition, lev-
ofloxacin MICs were determined for these 2 mutants by
using broth microdilution.
Competitive Growth of QRSP Mutants In Vitro  
Phe/Phe contained a GyrA: Ser81Phe mutation and a
ParC: Ser79Phe mutation. Phe/Tyr contained a GyrA:
Ser81Phe mutation and a ParC: Ser79Tyr mutation. In
vitro competition experiments were carried out between
EF3030 and Phe/Phe (N = 7) and between EF3030 and
Phe/Tyr (N = 12) by coincubating them in Todd-Hewitt
broth containing yeast extract (Difco, Detroit, MI, USA).
The number of generations of each strain was calculated as
previously described (4) by using the formula g = (logB –
logA)/(log2), where relative fitness (RF) = gres/gsus, g is the
number of generations, res is gemifloxacin-resistant trans-
formants (Phe/Phe or Phe/Tyr), sus is the gemifloxacin-
susceptible parent EF3030, B is the CFU/mL at time 1 (6
h), and A is the CFU/mL at time 0.
Murine Pneumonia Models
For both models of pneumococcal infection, 6-week-
old, female CBA/CaHN-Btkxid/J (CBA/N) mice (Jackson
Laboratories, Bar Harbor, ME, USA) were used. Infection
leading to pneumonia and colonization were induced over
a period of 7 days, and samples were obtained from
nasopharynges, lungs, and blood of mice as previously
described (19,20). The pneumonia model entailed anes-
thetizing the mouse by inhalation of isoflurane before
delivery of bacteria in 40 µL of lactated Ringer solution to
ensure delivery to the lungs. In the colonization model,
nonanesthetized mice were infected intranasally with bac-
teria in 10µL of lactated Ringer solution to ensure colo-
nization of the nasopharynx, as previously described
(19,20). All mouse experiments were carried out under the
approval of the Institutional Animal Care and Use
Committee at the University of Alabama at Birmingham.
Competitive Growth of QRSP Mutants In Vivo 
To determine relative nasopharyngeal growth during
colonization, 10 µL of a 1:1 mixture containing 106 CFUs
each of EF3030 and the fluoroquinolone-resistant mutant
(Phe/Phe or Phe/Tyr) were instilled into the nares as
described for the colonization model (20). Ten mice
received the EF3030 and Phe/Phe mixture, and 10 mice
received the EF3030 and Phe/Tyr mixture. 
To determine relative growth in the lungs, 40 µL of a
1:1 mixture containing EF3030 and the fluoroquinolone-
resistant mutant (Phe/Phe or Phe/Tyr) were instilled into
the nares as previously described for the pneumonia model
(19). For the EF3030 and Phe/Phe competitive infections,
9 mice received 104 CFUs of each strain, and 14 mice
received 106 CFUs of each strain. For the EF3030 and
Phe/Tyr competitive infections, 9 mice received 104 CFUs
of each strain, and 14 mice received 106 CFUs of each
strain. Initially, the lower dose was used because of con-
cerns for mouse mortality. When this turned out not to be
an issue, the infectious dose was raised to 106 CFU to
increase lung infection levels, yield more countable
colonies, and allow the effects of a range of infectious
doses to be examined. 
For recovery of EF3030 and mutants from mice in the
pneumonia and colonization models, mice were killed 7
days postinfection, samples were collected, and CFUs
were counted in nasal washes, lungs, and blood as
described previously (19,20). Serial dilutions of specimens
were cultured with gentamicin (which allowed growth of
EF3030 and both mutants but reduced growth of oral com-
mensal organisms) and with gemifloxacin (which allowed
growth of only Phe/Phe and Phe/Tyr). Samples were incu-
bated on blood agar plates containing 5 µg/mL gentamicin
with or without 0.08 µg/mL gemifloxacin at 37°C for 16 h
in a candle jar.
Percentage recovery units (PRUs) were determined for
bacteria recovered from mice co-colonized or coinfected
with both strains. PRUs were calculated by multiplying the
recovery ratio (CFUs recovered from nasal wash or lung
homogenate divided by CFUs used to infect mice
intranasally) by 106 (to simplify statistical comparisons
and facilitate visual comparisons). 
Noncompetitive Growth of QRSP Mutants in Vivo 
To establish noncompetitive pneumococcal infections
with EF3030, Phe/Phe, and Phe/Tyr, 106 CFUs were used
for colonizations, and 107 CFUs were used for lung infec-
tions, as described above. EF3030 was used to infect 39
mice (10 for colonization and 29 for pneumonia), Phe/Phe
was used to infect 25 mice (5 for colonization and 20 for
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colonization and 19 for pneumonia). Mice were killed after
7 days, and samples were collected and analyzed as
described above.
Statistical Analysis 
The Wilcoxon matched-pairs signed-rank test was used
to compare the numbers of generations for each competing
pair in in vitro competitive growth experiments and to
compare the PRUs in in vivo competitive infections. For
noncompetitive infections, PRUs of EF3030, Phe/Phe, and
Phe/Tyr were compared by using the Mann-Whitney
unpaired 2-tailed test. Statistical tests were conducted with
the InStat program (GraphPad Software, Inc., San Diego,




The QRDR mutations in gyrA and parC of the clinical
QRSP (donor strains CT01147 and UAB169), the mutants
(Phe/Phe and Phe/Tyr), and parent strain (EF3030) were
sequenced to confirm the presence of QRDR mutations
and because genetic transformation has been associated
with increased mutation frequency (21,22). The transfor-
mation fragment for gyrA consisted of 1,325 bp, of which
660 inclusive of the QRDR were sequenced. Likewise, the
transformation fragment for parC consisted of 778 bp, of
which 446 were sequenced. The gyrA and parC QRDR
mutations in the mutants (Phe/Phe and Phe/Tyr) matched
those of the corresponding donor strains (CT01147 and
UAB169). Phe/Phe also contained 2 additional synony-
mous, nonquinolone resistance–conferring mutations in
gyrA (data not shown). The levofloxacin MICs for the
Phe/Phe and Phe/Tyr mutants were both 16 µg/mL, verify-
ing the degree of resistance to the fluoroquinolone class of
antimicrobial agents.
Colonization Model 
Overall, EF3030 underwent more generations per 6-
hour in vitro growth period than either Phe/Phe (p<0.016)
(Figure 1A) or Phe/Tyr (p<0.007) (Figure 1B). Of 10 mice
intranasally infected with approximately equal amounts
(106 CFUs) of EF3030 and Phe/Phe, 8 were colonized.
Among these 8 mice, EF3030 outcompeted Phe/Phe
(p<0.023) (Figure 2A). Of 10 mice intranasally infected
with approximately equal amounts of EF3030 and Phe/Tyr,
8 were colonized. Among these 8 mice, EF3030 outcom-
peted Phe/Tyr (p<0.008) (Figure 2B).
When mice were infected intranasally with 106 CFUs of
EF3030, Phe/Phe, or Phe/Tyr, Phe/Phe and EF3030 were
recovered in similar numbers (p = 1.069), but Phe/Tyr was
recovered in much lower numbers than EF3030 (p<0.004)
(Figure 2C). Thus, although Phe/Phe was less efficient at
nasopharyngeal colonization when competing with
EF3030, it colonized as well as EF3030 when tested alone.
Phe/Tyr was less efficient than EF3030 at colonizing,
whether or not it was in direct competition with EF3030. 
Pneumonia Model 
Of the 23 mice infected with approximately equal
amounts (104 CFUs of each strain or 106 CFUs of each
strain) of EF3030 and Phe/Phe, all 23 were colonized
nasopharyngeally, and lung infection developed in 13 of
23. EF3030 outcompeted Phe/Phe in both the nasopharynx
(p<0.001) and the lungs (p<0.001) (Figure 3A). 
Of the 23 mice infected with approximately equal
amounts (104 CFUs or 106 CFUs of each) of EF3030 and
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Figure 1. In vitro competition between Streptococcus pneumoniae
EF3030 and the Phe/Phe mutant (A) and between EF3030 and the
Phe/Tyr mutant (B) in liquid medium (broth). Bars indicate medi-
ans. Lines connect strains competing in the same broth. p values
were calculated by the Wilcoxon matched-pairs signed-rank test.Phe/Tyr, all 23 were colonized nasopharyngeally, and lung
infections developed in 12 of 23. We observed no signifi-
cant difference in PRUs with the 2 different inocula.
EF3030 outcompeted Phe/Tyr in the nasopharynx
(p<0.008) but not in the lungs (p<0.176) (Figure 3B).
Thus, when anesthetized mice were infected with both
EF3030 and a mutant (Phe/Phe or Phe/Tyr), EF3030 out-
competed each mutant in the nasopharynx, but EF3030
outcompeted only Phe/Phe in the lungs.
Of the 29 mice monoinfected with 107 CFUs of
EF3030, 5 died of infection and 24 were colonized
nasopharyngeally. Lung infections developed in 19 of
these 24 (Figure 3C). Of the 20 mice monoinfected with
107 CFUs of Phe/Phe, 4 died of infection and 16 were col-
onized nasopharyngeally; lung infections developed in all
16. Of the 19 mice monoinfected with 107 CFUs of
Phe/Tyr, 5 died of presumed pneumonia, and 14 were col-
onized nasopharyngeally; lung infections developed in all
14. 
Among these monoinfections, EF3030 was recovered
from the nasopharynx in quantities significantly different
from those of Phe/Phe (p<0.001) and Phe/Tyr (p<0.001)
(Figure 3C). In the lungs, however, EF3030 was not recov-
ered in numbers significantly different those of from either
Phe/Phe (p = 0.453) or Phe/Tyr (p = 0.152). Thus, even in
the absence of competition, EF3030 was recovered in
higher numbers than those of both mutants in the
nasopharynx, but was not recovered in higher numbers
than those of either mutant in the lungs.
Discussion
Although fluoroquinolone resistance in S. pneumoniae
remains very low in North America, it has begun to
increase in recent years (15,23) and is especially high in
some Asian countries that already have high β-lactam and
macrolide resistance rates (24). Pneumococcal resistance
to fluoroquinolones is largely mediated by de novo point
mutations in the gyrA and  parC genes encoding DNA
gyrase and topoisomerase, respectively, in the QRDRs
(25). A specific single-point mutation in either of these
genes confers low-level resistance, with high-level resist-
ance generally requiring a point mutation in both gyrA and
parC  QRDRs. QRSP are generally clonally unrelated,
although there have been some reports of clonal dissemi-
nation, and fluoroquinolone resistance has now been
reported in several international clones (10–13,26). 
The fitness of pathogenic bacteria to cause disease
relies on several factors, including colonization of the host,
evasion of host defenses, propagation on or inside the host,
and transmission to a new host. Antimicrobial resistance
can be associated with a decrease in bacterial fitness
(3,27). A measure of fitness of antimicrobial-resistant
pathogens could aid in the prediction of the future rates of
Quinolone-resistant Streptococcus pneumoniae
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Figure 2. Percentage recovery units (PRUs: CFUs recovered from
nasal wash or lung homogenate divided by CFUs originally used
to infect mice and multiplied by 106) for competitive colonization
between  Streptococcus pneumoniae EF3030 and the Phe/Phe
mutant (A), EF3030 and the Phe/Tyr mutant (B), and noncompeti-
tive colonization of EF3030, Phe/Phe, and Phe/Tyr (C). Lines con-
nect data from the same mouse. Bars indicate median PRUs. NP,
nasopharynx. p values were calculated by the Wilcoxon matched-
pairs signed-rank test (A and B) and the Mann-Whitney unpaired
2-tailed test (C).disease caused by these bacteria, guide recommendations
for empiric therapy for some bacterial infections, and
direct the development of new antimicrobial drugs.
Although other studies have investigated the fitness of
antimicrobial-resistant pathogens including S. pneumoniae
(6,7), the focus has frequently been on resistance to β-lac-
tam antimicrobial drugs, and only a few have investigated
the relative fitness of QRSP (4,5).
In our current study, we sought to investigate the fitness
of QRSP mutants. We postulated that QRSP may have
reduced fitness because fluoroquinolone resistance rates
remain very low, and naturally occurring QRSP isolates are
generally clonally unrelated. When in competition with
EF3030, the Phe/Phe mutant, which contains the GyrA:
Ser81Phe and ParC: Ser79Phe mutation combination often
found in clinical QRSP(11,18,24,28–30), was inferior in all
3 models tested. However, in the absence of competition
with EF3030, Phe/Phe was only inferior in nasopharyngeal
colonization but was as able as EF3030 to produce lung
infection. Conversely, the Phe/Tyr mutant, which contains
the GyrA: Ser81Phe and ParC: Ser79Tyr mutation combi-
nation found more often in laboratory-selected mutants
than in clinical QRSP (18,24,28–30), was inferior in vitro
and in nasopharyngeal colonization but was as able as
EF3030 to produce lung infection, regardless of competi-
tion from EF3030. Though counterintuitive, this probably
occurred because of the nature of the lung infection model,
in which bacteria are intranasally instilled into anesthetized
mice without the prerequisite for nasopharyngeal coloniza-
tion. In fact, nasopharyngeal colonization resulting from
the lung infection model is more the result of retrograde
movement of bacteria from the lungs to the nasopharynx
than of initial collection of bacteria in the nasopharynx
when first infected. Why QRDR mutations tended to con-
fer more fitness costs in the nasopharyngeal mucosa than in
the lungs is not clear, but it is possible that commensal bac-
teria may have provided more competition in the nasophar-
ynx than in the lungs, and therefore the mutants displayed
greater fitness reductions when in competition with both
wild-type  S. pneumoniae and commensal bacteria.
Alternatively, phase variation in pneumococcal opacity
may play a role in the difference in fitness of the mutants in
the lung versus the nasopharynx, since the opaque phase
tends to predominate in invasion, and the transparent phase
predominates in colonization (31). These 2 phases express
very different complements of virulence factors, which
suggest that the processes involved in bacterial survival in
these 2 niches can be very different.
In mice that had been colonized and in those with lung
infections, fewer organisms were recovered than were
infected, i.e., no bacterial growth was detectable in the ani-
mals. It may be postulated that these models are simply
measuring the relative death rates of the Phe/Phe and
Phe/Tyr mutants, as compared to EF3030, and not actual
survival and growth. In a study by Balachandran et al.
(32), evidence was presented indicating that pneumococci
multiply during colonization. To our knowledge, no stud-
ies have investigated pneumococcal turnover in the lung,
but since the lungs of CBA/N mice contain many neu-
trophils (33), the bacteria would likely have to multiply to
compensate for being killed, based on the number of bac-
teria recovered from the lungs.
Although several studies have investigated the fitness
of antimicrobial-resistant pathogens (8,34,35) and antimi-
crobial-resistant  S. pneumoniae (6,7,36,37), few have
investigated the fitness of fluoroquinolone-resistant bacte-
ria (4,5). Our results are in contrast to those of Gillespie
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Figure 3. Percentage recovery units (PRUs: CFUs recovered from
nasal wash or lung homogenate divided by CFUs originally used
to infect mice and multiplied by 106) for competitive pneumonia
infection with Streptococcus pneumoniae EF3030 and the
Phe/Phe mutant (A), EF3030 and the Phe/Tyr mutant (B), and
noncompetitive pneumonia with EF3030, Phe/Phe, and Phe/Tyr
(C). Lines connect data from the same mouse. Bars indicate medi-
an PRUs. NP, nasopharynx. p values were calculated by the
Wilcoxon matched-pairs signed-rank test (A and B) and the Mann-
Whitney unpaired 2-tailed test (C).et al. (4), who found a significant decrease in the relative
fitness of Tyr/Tyr, but not of Phe/Tyr, compared to wild-
type, in in vitro growth experiments with S. pneumoniae.
Conversely, our results are supported by Giraud et al. (8),
who reported a decrease in relative fitness in high-level
fluoroquinolone-resistant  Salmonella enterica serovar
Typhimurium in in vitro growth and chicken gut coloniza-
tion experiments, and by Azoulay-Dupuis et al. (5), who
demonstrated that clinical strains of QRSP were less viru-
lent in outbred mice than a quinolone-susceptible laborato-
ry strain and its quinolone-resistant isogenic mutant.
If QRSP are less efficient than fluoroquinolone-suscep-
tible S. pneumoniae at colonizing humans, the result could
explain the few reports of clonal lineages of QRSP.
Nasopharyngeal colonization precedes pneumonia and is
the reservoir from which person-to-person transmission
occurs (38). Therefore, a pneumococcus that is inefficient
in colonizing the nasopharynx would be less efficient in
producing lung infection, no matter how efficiently the
organism infects the lungs; likewise, this organism would
be less likely to disseminate clonally in the community.
However, the fact that lung infection is not attenuated by
fluoroquinolone resistance indicates that the resistant
strains selected in patients by antimicrobial treatment may
still cause severe disease, and possibly death, as has been
reported (39,40).
We have attempted to measure the relative fitness of the
2 most commonly occurring QRDR mutation combina-
tions. While different mutations may have different affects
on fitness, we found that strains containing these common
QRDR mutations appeared to have reduced fitness in the
absence of antimicrobial drugs both in vitro and in vivo.
Thus, QRSPmay have reduced ability to initiate infections
in the absence of fluoroquinolone selection and may be
inefficient at displacing resident susceptible strains and
therefore causing disease. This suggests that the judicious
use of antimicrobial drugs may keep the prevalence of
QRDR clones low because of their relatively low fitness.
The few reports of clonal spread of QRSP and of fluo-
roquinolone resistance in multidrug-resistant isolates raise
the possibility that these isolates may have already
acquired compensatory mutations. Continued surveillance
is very important in understanding the epidemiology of
QRSP. Overall, fluoroquinolone resistance rates remain
very low, most resistance arises in genetically diverse
strains, and clonal dissemination is likely still not a major
contributor to the appearance of QRSP. 
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